CD38 and plasma cell myeloma: Krejcik et al. identified a novel subpopulation of Treg cells expressing CD38 in the peripheral blood of patients with relapsed/refractory multiple myeloma, which was more immunosuppressive in vitro than CD38-negative Tregs and was reduced in Dara-treated patients (24).